Genomic imprinting and cancer; new paradigms in the genetics of neoplasia.
The role of epigenetic modification of gene expression is becoming increasingly important in how we understand the loss of tumour suppressor gene function in a variety of tumours and tumour predisposing syndromes. This review explores the importance of epimutation in Beckwith-Wiedemann syndrome and Wilms' tumour and focuses on genomic methylation in both imprinted and non-imprinted genes as a key mechanism in the development of cancer.
Schofield
P N
PN
Laboratory of Stem Cell Biology, Department of Anatomy, University of Cambridge, Downing Street, CB2 3DY, Cambridge, UK. ps@mole.bio.cam.ac.uk
Joyce
J A
JA
Lam
W K
WK
Grandjean
V
V
Ferguson-Smith
A
A
Reik
W
W
Maher
E R
ER
D000375:Aging; D001506:Beckwith-Wiedemann Syndrome / Q000235:genetics; D019175:DNA Methylation; D020868:Gene Silencing; D016147:Genes, Tumor Suppressor; D018392:Genomic Imprinting; D006801:Humans; D007335:Insulin-Like Growth Factor II / Q000235:genetics; D005810:Multigene Family; D009369:Neoplasms / Q000235:genetics*
D007335:Insulin-Like Growth Factor II